Figure 5.
Major bleedings in different dosing regimens in moderate and severe disease cohorts [20,21,22,23,24,25,50,51,52,53,54,55,56]. (A) Major bleeding events in severe and moderate disease cohorts; (B) major bleeding events in cohorts where intermediate or therapeutic dose was used in the HD group.